Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Hypocretin in cerebrospinal fluid is positively correlated with Tau and pTau.

Deuschle M, Schilling C, Leweke FM, Enning F, Pollmächer T, Esselmann H, Wiltfang J, Frölich L, Heuser I.

Neurosci Lett. 2014 Feb 21;561:41-5. doi: 10.1016/j.neulet.2013.12.036.

PMID:
24373987
2.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
3.

Association between hypocretin-1 and amyloid-β42 cerebrospinal fluid levels in Alzheimer's disease and healthy controls.

Slats D, Claassen JA, Lammers GJ, Melis RJ, Verbeek MM, Overeem S.

Curr Alzheimer Res. 2012 Dec;9(10):1119-25.

PMID:
22742854
4.

Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.

Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L.

J Alzheimers Dis. 2010;21(2):471-8. doi: 10.3233/JAD-2010-091594.

PMID:
20555147
5.

Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease.

Liguori C, Romigi A, Nuccetelli M, Zannino S, Sancesario G, Martorana A, Albanese M, Mercuri NB, Izzi F, Bernardini S, Nitti A, Sancesario GM, Sica F, Marciani MG, Placidi F.

JAMA Neurol. 2014 Dec;71(12):1498-505. doi: 10.1001/jamaneurol.2014.2510.

PMID:
25322206
6.

Cerebrospinal fluid biomarkers of Alzheimer's disease in Chinese patients: a pilot study.

Shea YF, Chu LW, Zhou L, Li WM, Lin OY, Chan MN, Xu A, Wong R, Ho TY, Liu KW, Ha J, Daniel TW, Song YQ, Lam KS.

Am J Alzheimers Dis Other Demen. 2013 Dec;28(8):769-75. doi: 10.1177/1533317513504615.

PMID:
24085246
7.

CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.

Alves G, Brønnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E.

J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1080-6. doi: 10.1136/jnnp.2009.199950.

PMID:
20547614
8.

Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease.

Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, Scheltens P, Blankenstein MA.

Clin Chem. 2010 Feb;56(2):248-53. doi: 10.1373/clinchem.2009.130518.

9.

Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study.

Jongbloed W, Kester MI, van der Flier WM, Veerhuis R, Scheltens P, Blankenstein MA, Teunissen CE.

Alzheimers Dement. 2013 May;9(3):276-83. doi: 10.1016/j.jalz.2012.01.004.

PMID:
23110867
10.

Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias.

Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H, Marksteiner J, Humpel C.

Dement Geriatr Cogn Disord. 2006;21(1):9-15.

PMID:
16244482
11.

Cerebrospinal fluid profiles of amyloid β-related biomarkers in Alzheimer's disease.

Rosén C, Andreasson U, Mattsson N, Marcusson J, Minthon L, Andreasen N, Blennow K, Zetterberg H.

Neuromolecular Med. 2012 Mar;14(1):65-73. doi: 10.1007/s12017-012-8171-4.

PMID:
22350541
12.

Cerebrospinal fluid biomarkers in Alzheimer's disease and geriatric depression: preliminary findings from Brazil.

Reis T, Brandão CO, Freire Coutinho ES, Engelhardt E, Laks J.

CNS Neurosci Ther. 2012 Jul;18(7):524-9. doi: 10.1111/j.1755-5949.2012.00311.x.

PMID:
22530600
13.

CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.

Aerts MB, Esselink RA, Claassen JA, Abdo WF, Bloem BR, Verbeek MM.

J Alzheimers Dis. 2011;27(2):377-84. doi: 10.3233/JAD-2011-110482.

PMID:
21841257
14.

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P.

Arch Neurol. 1998 Jul;55(7):937-45.

PMID:
9678311
15.

Increased cerebrospinal fluid levels of nerve cell biomarkers in narcolepsy with cataplexy.

Heier MS, Skinningsrud A, Paus E, Gautvik KM.

Sleep Med. 2014 Jun;15(6):614-8. doi: 10.1016/j.sleep.2014.02.005.

PMID:
24784789
16.

Cerebrospinal fluid levels of Aβ42 relationship with cholinergic cortical activity in Alzheimer's disease patients.

Martorana A, Esposito Z, Di Lorenzo F, Giacobbe V, Sancesario GM, Bucchi G, Bonnì S, Bernardini S, Sorge R, Sancesario G, Bernardi G, Caltagirone C, Koch G.

J Neural Transm (Vienna). 2012 Jul;119(7):771-8. doi: 10.1007/s00702-012-0780-4.

PMID:
22402892
17.

Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia.

Laske C, Stransky E, Fritsche A, Eschweiler GW, Leyhe T.

Eur Arch Psychiatry Clin Neurosci. 2009 Mar;259(2):80-5. doi: 10.1007/s00406-008-0838-3.

PMID:
18806919
18.

Hypocretin (orexin) loss in Alzheimer's disease.

Fronczek R, van Geest S, Frölich M, Overeem S, Roelandse FW, Lammers GJ, Swaab DF.

Neurobiol Aging. 2012 Aug;33(8):1642-50. doi: 10.1016/j.neurobiolaging.2011.03.014.

PMID:
21546124
19.

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L.

Lancet Neurol. 2006 Mar;5(3):228-34. Erratum in: Lancet Neurol. 2006 Apr;5(4):293.

PMID:
16488378
20.

Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease.

Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, Van Kamp GJ, Van Swieten JC, Scheltens P.

Neurology. 2004 May 11;62(9):1580-4.

PMID:
15136685

Supplemental Content

Support Center